Mineralocorticoid Receptor Blockade in Chronic Kidney Disease

被引：0
作者：
Matthew J. Volk
Andrew S. Bomback
Philip J. Klemmer
机构：
[1] University of North Carolina-Chapel Hill,UNC Kidney Center
[2] University of North Carolina at Chapel Hill,Department of Medicine, Division of Nephrology and Hypertension
[3] Columbia University College of Physicians and Surgeons,Department of Medicine, Division of Nephrology
来源：
Current Hypertension Reports | 2011年 / 13卷
关键词：
Aldosterone; Aldosterone breakthrough; Mineralocorticoid blockade; Chronic kidney disease; CKD; Extracellular volume; Bioimpedance; Tissue inflammation; Hyperkalemia; Hypertension;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Aldosterone antagonists have been highly successful in treating congestive heart failure and resistant hypertension. Until recently, therapies targeting the mineralocorticoid receptor in chronic kidney disease (CKD) have received little attention, largely because of the risk of hyperkalemia and the incorrect assumption that traditional therapy with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or both consistently reduces activity of the renin-angiotensin system in all patients. Control of extracellular volume and low-dose mineralocorticoid receptor blocker therapy may offer additional antihypertensive and anti-inflammatory benefits in select CKD populations.
引用
收藏
页码：282 / 288
页数：6
相关论文
共 250 条
[1]  
Bomback AS(2007)The incidence and implications of aldosterone breakthrough Nat Clin Pract Nephrol 3 486-492
[2]  
Klemmer PJ(1999)The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 709-717
[3]  
Pitt B(2003)Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309-1321
[4]  
Zannad F(1975)Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a “no-salt” culture Circulation 52 146-151
[5]  
Remme WJ(1972)Essential hypertension: renin and aldosterone, heart attack and stroke N Engl J Med 286 441-449
[6]  
Cody R(2009)isordered aldosterone-volume relationship in end-stage kidney disease J Renin Angiotensin Aldosterone Syst 10 230-236
[7]  
Castaigne A(2008)Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension 51 1252-1258
[8]  
Perez A(2010)Aldosterone: role in the cardiometabolic syndrome and resistant hypertension Prog Cardiovasc Dis 52 401-409
[9]  
Pitt B(2009)Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension Ann Intern Med 150 776-783
[10]  
Remme W(2010)Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome Clin J Am Soc Nephrol 5 1132-1140
12345678910